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Abstract 
Objective: To ascertain major risk factors associated with 
pulmonary exacerbation and pulmonary function decline 
in cystic fibrosis. 
Method: The systematic review was conducted at Aga 
Khan University, Karachi, in September 2018, and 
comprised electronic search of PubMed, Ovid, Science 
Direct and Cumulative Index of Nursing and Allied Health 
Literature databases of studies conducted from January 
1990 to September 2018 which were categorised into 3 
sets; 1990-98, 1999-2007 and 2008-18. Studies included 
for review focussed on articles with pulmonary 
exacerbation as the health outcome indicator, and had 
diagnosis of cystic fibrosis as the inclusion criteria, while 
risk factors were the exposure terms used in the search 
process. References in bibliographies of the included 
studies were also systematically searched for relevant 
documents. 
Results: Of the 60 studies obtained, 31(51.7%) were 
selected; 2(6.45%) from 1990-98, 7(22.58%) from 1999-
2007 and 22(70.96%) from 2008-18. Overall, 17(54.83%) 
were cohort studies, 7(22.5%) were cross-sectional 
studies, 3(9.6%) were case-control studies, 3(9.6%) were 
randomised controlled trials and 1(3.2%) was systematic 
review and meta-analysis. In terms of major risk factors, 
genetic mutations were cited by 4(12.9%) studies, 
infections and inflammatory biomarkers by 15(48.4%), 
nutritional deficiencies by 9(29%) and geographical and 
socioeconomic status by 3(9.6%) studies. 
Conclusion: Early identification and recognition of risk 
factors associated with pulmonary exacerbation can have 
an explicit impact on its management, leading to 
decreased morbidity and mortality burden in cystic 
fibrosis cases. 
Keywords: Pulmonary exacerbation, Cystic fibrosis, Risk 
factors, Systematic review. 
DOI: https://doi.org/10.47391/JPMA.04-515 
Introduction 
Cystic fibrosis (CF) is an inherited disorder affecting 
multiple organ systems. Autosomal recessive mutation of 
the cystic fibrosis transmembrane conductance regulator 
(CFTR) gene on chromosome 7 plays a pivotal role in 
pathogenesis. Major morbidity and mortality are 
attributed to pulmonary manifestations of CF. Infections 
comprise the major lung disease burden. Structural and 
functional decline in pulmonary parenchyma occurs with 
recurrent pulmonary exacerbations. In the United States, 
1 out of every 3,200 Caucasian births have CF. Current 
medical advancements and research developments have 
increased median survival to the 4th decade. However, 
patients still experience shortened life expectancy 
secondary to devastating pulmonary manifestations and 
progressive lung function decline.1 
Pulmonary exacerbation is as an escalation of the 
pulmonary decline with deterioration in forced expiratory 
volume in 1 second (FEV1), nutritional decline, regression in 
daily functioning and quality of life (QOL). Progressive lung 
descent is the central determinant of disease outcome in 
CF.2 Pulmonary exacerbation serves as a key indicator for 
disease severity and is a crucial variable in studies assessing 
overall survival (OS) related to CF. Moreover, lung disease 
remains the primary target for pivotal treatments 
decreasing morbidity and mortality in CF. Multiple risk 
factors associated with pulmonary manifestations 
contributing to exacerbations have been identified. These 
include nutritional deficiencies, infections, medications, 
biochemical markers indicating acute episodes and the 
effect of socioeconomic status (SES).3 
Identification of risk factors has a vital role in treatment and 
can improve management outcomes in CF population 
which in turn can affect life-expectancy and rate of 
exacerbations. 
The current study was planned to systematically review 
literature to recognise risk factors correlated with 
pulmonary exacerbations in CF. 
Methods 
The systematic review was conducted at Aga Khan 
University, Karachi, and comprised electronic search of 
PubMed, Ovid, Science Direct and Cumulative Index of 
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Nursing and Allied Health Literature (CINAHL) databases 
of studies conducted from January 1990 to September 
2018 which were categorised into 3 sets; 1990-98, 1999-
2007 and 2008-18. The year 1990 was set as the starting 
point for literature search to maintain relevance. 
The initial database search was done in September 2018 
followed by screening of articles. The review of relevant 
full text completed in the last quarter of 2018, and the 
manuscript was finalised in the first quarter of 2019. 
The search covered all reports in indexed and non-
indexed local and international English-language journals 
which described primary epidemiological research 
concerning risk factors for pulmonary exacerbation in CF 
in Asian populations. Studies included for review 
focussed on articles with pulmonary exacerbation as the 
health outcome indicator, and had diagnosis of cystic 
fibrosis as the inclusion criteria, while risk factors were the 
exposure terms used in the search process. References in 
bibliographies of the included studies were also 
systematically searched for relevant documents. 
Full-text copies of all the studies found were scrutinised. 
Those that met the inclusion criteria were then abstracted 
and summarised using a standardised form. Following the 
initial electronic search carried out independently by all the 
authors, decisions and abstracted summaries were 
compared and disparities were settled through discussion. 
For the development of protocol, manuscript and reporting 
of study findings, Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) guidelines were 
used.4 Quality assessment of the studies was done using the 
Newcastle-Ottawa scale (NOS) for cross-sectional and 
cohort studies,5 interpreted as per the given criteria; Good 
quality: 3 or 4 stars in selection domain AND 1 or 2 stars in 
comparability domain AND 2 or 3 stars in 
outcome/exposure domain; Fair quality: 2 stars in selection 
domain AND 1 or 2 stars in comparability domain AND 2 or 
3 stars in outcome/exposure domain; Poor quality: 0 or 1 
star in selection domain OR 0 stars in comparability domain 
OR 0 or 1 stars in outcome/exposure domain". Cochrane risk 
of bias tool was used for interventional studies.6 
In assessing publications apposite for review, findings 
were assembled by health outcomes, and conclusions 
were measured that could be drawn given the strengths 
and limitations of each study. 
Results 
Of the 60 studies obtained, 31(51.7%) were selected 
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Figure: Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) flow-chart.
(Figure). Of them, 2(6.45%) were from the 1990-98 period, 
7(22.58%) from 1999-2007 and 22(70.96%) from 2008-18. 
Overall, 17(54.83%) were cohort studies, 7(22.5%) were 
cross-sectional studies, 3(9.6%) were case-control studies, 
3(9.6%) were randomised controlled trials (RCTs) and 
1(3.2%) was systematic review and meta-analysis (Table-
1). Of the 17(54.83%) cohort studies, 13(76%) were of 
good quality and the remaining 4(24%) had fair quality. 
All the 7(22.5%) cross-sectional studies had good quality. 
In terms of major risk factors, genetic mutations were 
cited by 4(12.9%) studies, infections and inflammatory 
biomarkers by 15(48.4%), nutritional deficiencies by 
9(29%) and geographical location and SES by 3(9.6%) 
studies (Table-2). 
In terms of genetic mutations, a 2011 study analyzed 
correlation between CFTR class I and class II mutations in 
CF patients, and determined that two class I mutations 
were linked with grave pulmonary functional decline in 
contrast to two class II mutations or combination of 
classes I and II.7 A 2002 study proposed that pulmonary 
disease showed an association with severity of CFTR 
mutations. Precarious disease with earlier onset (1.7 years 
vs 7.9 years, p=0.0001) was seen in patients with two 
severe mutations, and they displayed critical respiratory 
impairment, mean FEV1 decline (29% of predictive value 
vs 58% of predictive value, p<0.001); high pseudomonas 
(P.) colonisation (97% vs 57%, p<0.01); prominent 
occurrence of end-stage respiratory disease, having FEV1 
<30% (73% vs 29%, p<0.05); and with pronounced 
regression of FEV1 (3% vs 1.4%, p<0.001) annually. 
Multivariate logistic regression analysis, containing two 
extreme mutations, was self-governing indicator of an 
existence constraining respiratory deficiency (relative 
hazard, 6.75; 95% confidence interval [CI] 1.79-26.50, 
p=0.003).8 
A retrospective observational study in 2015 
demonstrated that mean yearly deterioration in FEV1% 
predicted was 1.01%. Homozygous F508del mutations 
showed a large decrease in FEV1. Moreover, pulmonary 
regression was associated with female gender, low body 
mass index (BMI), recurrent/productive cough, one or 
more pulmonary exacerbation, high FEV1 (>/=115% 
predicted), methicillin-sensitive staphylococcus aureus 
(MSSA), methicillin-resistant staphylococcus aureus 
(MRSA) or stenotrophomonas (S.) maltophilia-positive 
cultures.9 A 1997 study, with a large cohort from CF 
database, showed that the patients deceased prior to age 
15 had a considerably reduced lung function compared to 
their first test and had a fleeting drop in pulmonary 
function. Lung deterioration was pronounced in delta 
F508 mutation homozygotes compared to delta F508 
mutation heterozygotes. Females had a noteworthy 
precipitous waning than males, and those with pancreatic 
insufficiency had exorbitant regression than those with 
good pancreatic function.10 
Infections and inflammatory biomarkers were identified 
by 15(48.4%) studies. A prospective 2004 study 
established that a new pulmonary exacerbation in 
majority of patients was not secondary to the attainment 
of new P. aeruginosa strain. Further, 40(48%) patients 
required intravenous (IV) antibiotics for exacerbation, 
while 36(43%) patients had genetically typeable P. 
aeruginosa isolates, amd in 34(96%) of these 36 patients, 
strains recovered during exacerbation and clinical 
stability were of the same genotype. Only 2(6%) patients 
(95% CI 0-18%) had clone P. aeruginosa strain cultured 
during exacerbation.11 A multicentre study in 2014 found 
a correlation between P. aeruginosa phenotypes during 
infection stages and their prognostic value in pulmonary 
exacerbation prediction. It concluded that two in vitro 
phenotypes differentiated early and late stages of 
infection: pyoverdine production (31% of new cultures, 
48% of intermittent, 69% of chronic) and low protease 
production (31%, 39%, 65% respectively). Mucoidy (odds 
ratio [OR] 1.75, 95% CI 1.19-2.57) and reduced twitching 
motility (OR 1.43; 95% CI 1.11-1.84) were strong predictors 
for succeeding exacerbations in the following 2 years.12 A 
review in 2012 set out to assess the effectiveness of 
antibiotics in patients with chronic Burkholderia cepacia 
complex infection, determining it as a distinguishing 
infection in CF population, and found a deficiency of trial 
evidence to establish definite results.13 
A cross-sectional and retrospective cohort in 2011 
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Table-1: Duration and type of studies. 
 
Total of n=31 studies included, from 1990-2018. The timeline was divided into three 
stages: 
-      1990-1998= 2 studies 
-      1999-2007=7 studies 
-      2008-2018=22 studies 
-      Cohort studies=54.83% (17) 
-      Cross-sectional studies=22.5 % (7) 
-      Case-control studies= 9.6 % (3) 
-      Randomized controlled trials= 9.6 % (3) 
-      Systematic Reviews/Meta-analysis= 3.2 % (1)
Table-2: Themes for analysis. 
 
Risk factors associated with Pulmonary exacerbation in Cystic Fibrosis: (n=31) 
-      Genetic mutations (n=4) 
-      Infections and Inflammatory biomarkers (n=15) 
-      Nutritional deficiencies (n=9) 
-      Geographic and socioeconomic status (n=3)
recognised stenotrophomonas (S.) maltophilia as an 
autonomous risk factor for pulmonary decline. Patients 
infected chronically with S. maltophilia were found to 
have mean antibody titers to bacterial flagellin (p<0.0001) 
and antibody titers to whole bacterial cell (p=0.0004) 
substantially high compared to patients with no or 
intermittent infections. Pulmonary exacerbation risk 
demanding hospitalisation and antibiotics was noticeable 
in patients infected with S. maltophilia compared to 
uninfected patients (relative risk [RR] 1.63, p=0.0002).14 A 
prospective study in 2013 recognised a marked risk of 
pulmonary exacerbation with viral infections (OR 2.19, 
95% CI 1.56-3.08, p<0.001) and antibiotic need in CF 
patients (OR 2.26, 95% CI 1.63-3.13, p<0.001).15 
The remaining 10(66.6%) studies in the category were 
related to biomarkers. A cohort study in 2015, conducted 
to find blood-based biomarkers to foresee impending CF 
pulmonary exacerbations using specific proteomics, 
established the likelihood of imminent exacerbations 
prediction with the use of multiple reaction monitoring 
mass spectrometry (MRM-MS) in which protein panel 
(area under the curve [AUC] 0.74) had the AUC in contrast 
to FEV1% predicted (AUC 0.55), C-reactive protein (CRP) 
(AUC 0.61) and interleukin-6 (IL-6) (AUC 0.60) which were 
the chief biomarkers correlated in exacerbation 
prediction.16 A case-control study in 2007 found a rise in 
OS and sputum levels of bioactive lipid mediators during 
an exacerbation. The sputum 8-iso-prostaglandin F2a (8-
iso-PGF2a) levels were high in acutely ill CF patients 
(p<0.001) along with high cysteinyl leukotrienes (cys-LT) 
and prostaglandin E2 (PGE2) levels. Sputum total cell 
count (p=0.03) regressed with antibiotic treatment, but 8-
iso-PGF2a, cys-LT or PGE2 levels remained unaffected, 
indicating the need of also addressing this respective 
aspect of CF management.17 A cohort in 2014 concluded 
that 37(70%) of 53 patients suffered pulmonary 
exacerbations during the study period. At baseline, 
reduced pulmonary function, lower clinical scoring and 
QOL values were related with increased risk of 
exacerbation events. Pulmonary exacerbations were 
associated with increased inflammatory markers at 
baseline on the first day, and treatment led to 
improvements in the levels of biomarkers. CRP and IL-8 
were the main biomarkers identified and they correlated 
with an early re-exacerbation.18 
A double-blinded RCT concluded that subjects treated 
with liposomal prostaglandin E1 (TLC C-53) had a less 
rapid pulmonary functional decline compared to controls 
(FEV mean difference 4.3%, 95% CI -6.8-15.4%) and had 
more time till next exacerbation (26 weeks against 11.9 
weeks). The biomarkers used as primary outcome 
determinants were IL-6, IL-8 and sputum neutrophil 
elastase.19 A study in 1999 concluded that OS, activity of 
free radicals and subsequent damage and their response 
to treatment parameters were high during pulmonary 
exacerbations and showed  improvements with 
treatment.20 
A cohort study measured levels of desmosine in the 
sputum of CF patients during pulmonary exacerbation 
treatment, and established significant decrease in 
desmosine during the first week of hospitalisation 
(p=0.04). A definite association was found in desmosine 
levels, plasma CRP (p=0.59; p=0.03), sputum IL-8 (p=0.86; 
p<0.01), and sputum neutrophil elastase (p=0.78, 
p<0.01).21 A prospective study in 2011 aimed at 
establishing the role of baseline procalcitonin levels in CF 
paediatric population and relation of the values with 
onset of pulmonary exacerbation. It established that 
baseline procalcitonin (n=92) was 0.05±0.07ng/ml, and at 
admission for in-patient management of exacerbation 
(m=22) it was 0.07±0.06ng/ml; not distinct from levels 
reported in healthy children.22 A cross-sectional study in 
2014 established the role of soluble cluster of 
differentiation 14 (sCD14) as a biomarker in recognising 
patients at risk of experiencing a CF exacerbation. It found 
sCD14 levels high during exacerbations (p=0.03) and in 
patients with IV antibiotics due to exacerbation within 4 
months of a steady clinical course (p=0.001).23 
An observational study in 2010 established a reduction in 
sputum calprotectin after treatment of an exacerbation 
(p<0.05). A substantial decrease was found in serum levels 
of calprotectin (p=0.002), CRP (p=0.002) and vascular 
endothelial growth factor (VEGF) (p=0.013). Moreover, 
serum calprotectin showed predictive value for interval 
towards next exacerbation (p=0.032) post-treatment.24 
One study in 2000 studied an elevation in mean VEGF 
levels in pulmonary disease patient groups, including CF 
and other lung diseases, and compared reference values, 
finding higher VEGF in CF (p=0.02). The study showed an 
inverse relation between VEGF and FEV1 in CF, (r-0.51, 
p=0.007). Following antibiotics, VEGF levels regressed in 
CF exacerbation (p=0.001).25 
With respect to nutritional sdeficiencies, a 2014 study 
using the CF database established that low BMI, 
pancreatic insufficiency, CF-related diabetes and P. 
aeruginosa infection had significant (p<0.001) impact on 
FEV1. Patients with low BMI had higher OR (95% CI 5.0-
7.3) of experiencing a debilitating pulmonary decline, 
pancreatic insufficiency had more risk (95% CI 1.6-2.5) and 
two-fold increase in OR of severe lung disease, and CF-
related diabetes patients had 1.8 times increased OR (95% 
CI 1.6-2.2) in contrast to unaffected patients.26 A cohort 
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study in 2008 indicated a gradual rate of pulmonary 
deterioration in patients with good nutritional state, 
slower BMI decline, lack of P. aeruginosa infection and 
Dornase alfa (Pulmozyme) therapy introduction at an 
early age.27 
A prospective, observational study in 2013 established a 
positive association between stronger pulmonary system 
at 6-18 years of age and weight-for-age percentile (WAP) 
>10% at age 4. Patients aged 18 years with WAP >50% at 
age 4 had less acute exacerbations, limited hospital stay 
and lower rate of diabetes. Good weight during 
childhood correlated with greater height, better 
pulmonary function, reduction in CF complications and 
improved survival through age 18.28 
With respect to vitamin D, a 2016 RCT indicated that high-
dose vitamin D3 had anti-catabolic effects in pulmonary 
exacerbations of CF.1 Another RCT done in 2012 showed a 
decrease in inflammatory markers, like tumour necrosis 
factor-alpha (TNF-a) (p<0.001, 50.4% decrease) and IL-6 
(p=0.09, 64.5% decrease) in subjects given high-dose 
vitamin D during an exacerbation, supporting the role of 
vitamin D in inflammation regulation.29 An ongoing RCT is 
assessing the impact of vitamin D in CF-related 
pulmonary exacerbation, but is yet to publish its findings1 
A cohort study in 2013 indicated that vitamin D-deficient 
patients had a substantially higher rate of exacerbations 
(13.1/10) patient-year compared to patients with vitamin 
D insufficiency (4.3/10) patient-year.30 One case-control 
study in 2012 showed pronounced bacterial colonisation 
in vitamin D-deficient patients (p<0.001) along with 
increased airway inflammation with increased markers 
myeloperoxidase (MPO) (p=0.007), IL-8 (p<0.001), TNF-a 
(p=0.03) and FEV1 decline.31 
A cross-sectional study in 2016 evaluated folate and 
vitamin D deficiency, and found an enhanced degree of 
atopy in patients with folate deficiency and a 2.2 times 
odd of acquiring at least one asthma exacerbation (95% CI 
1.1-4.6). Patients with both folate and vitamin D 
insufficiencies had  eight-fold amplified OR of one or 
more severe asthma exacerbation (95% CI 2.7-21.6).32 
A cohort study in 1996 assessed vitamin A status and 
suggested plasma retinol concentrations regressed in 
acute pulmonary exacerbation. Overall, 8 of 35 subjects 
had plasma retinol levels in the deficient range 
(<0.07micromol/L), mean concentrations of plasma 
retinol-binding protein (RBP) increased during 
hospitalisation (1.46 to 2.24 micromol/L), and CRP 
declined.33 Another study in 2004 indicated a very large 
cohort of CF being deficient in antioxidants. 
Deficiencies of carotenoids and vitamin E occurred in 
early disease, and antioxidant levels decreased with 
subsequent lung infections.34 
Finally, with respect to geographical status and SES, a study 
in 2016 showed regional variability in hospital stay duration 
and risks for subsequent hospitalisations for CF patients in 
the US; with the western region having longer length of 
inpatient stay. Northeast had decreased risk of 
hospitalisation (p=0.038), and the Caucasians in the south 
had lower risk compared to African Americans (p=0.0009, 
hazard ratio 0.79)35 A study in 2011 investigated the impact 
of SES and found that it had little impact on the treatment 
of exacerbations, but IV antibiotics were frequently 
prescribed for patients with low SES.36 A cohort study in 
2017 assessed the association of outcomes, including lower 
SES and tobacco smoke exposure, and found that these 
variables had significant correlation with decreased FEV1% 
predicted, poorer lung function and nutritional decline.2 
Discussion 
Progressive lung disease and functional decline are chief 
roots of morbidity and mortality in CF. The critical genetic 
factors noted through literature review were delta F508 
mutations and CFTR mutations.9,10 Homozygous 
mutations showed a swift regression in pulmonary 
function compared to heterozygous mutations. High-risk 
genotype population for CFTR mutations showed 
pronounced risk for respiratory decline.8 Severity of 
mutations was addressed in two studies, showing 
patients with two severe mutations manifested earlier 
disease onset and severe respiratory impairment.7 
Infectious agents highlighted in the studies reported 
significant P. aeruginosa association with pulmonary 
exacerbation and respiratory symptoms.11,12 S. 
maltophilia14 and burkholderia (B.) cepacian13 were 
among the other infections implicated in causing 
pulmonary decline. Viral respiratory infection was 
associated with exacerbations in one of the studies.15 
Inflammatory biomarkers were reported as indicators of 
acute exacerbations, like CRP, Leukotriene B4 (LTB4) and 
IL-6.24 Calprotectin, CRP and VEGF showed a decline in 
serum and sputum levels following exacerbation 
treatment, implicating their role in acute episodes and a 
negative correlation with FEV1.24 Sputum desmosine 
levels in a study showed a positive association with 
inflammation and declined following treatment.21 Also, 
sCD14 levels were found to be substantially pronounced 
in patients who suffered an exacerbation and exhibited a 
role in predicting subsequent exacerbations.23 Overall, 
biomarkers can be used to predict, measure severity and 
responsiveness of treatment and tailor management. 
Studies showed that patients with lower BMI and 
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pancreatic insufficiency presented with severe lung 
decline than pancreatic-sufficient patients. Better weight 
and height were associated with less complications and 
improved lung function.27 Vitamin deficiencies were 
highlighted, showing a positive correlation with 
pulmonary function and bouts of exacerbations. Vitamin 
D was also underscored, and it was found to have an anti-
catabolic effect and inflammation reduction.1 In another 
study, higher incidence of exacerbations and airway 
inflammation was linked to vitamin D deficiency.30 
Deficiencies of vitamin A, vitamin E, carotenoids and 
antioxidants showed positive associations with disease 
progression.33,34 
Geographic and regional variability was reported in the 
US, with the western region showing increased risks and 
subsequent hospitalisations compared to the northeast.35 
Caucasians in the south showed lower risk relative to 
African Americans. SES was emphasised in two studies, 
showing that low SES and tobacco exposure had a role in 
lung function decline, and antibiotics were frequently 
prescribed to patients belonging to low SES.2,36 
A systematic review in 2016 defined the rate of 
pulmonary regression in CF and identified influencing risk 
factors, while also summarising some findings about 
potential risk factors similar to the current review.37 
The current review, along with the mentioned factors, 
analysed data describing other potential indicators, like S. 
maltophilia, viral infections and certain biomarkers 
showing correlations with both progression and 
management of respiratory disease, stressing their role in 
aiding diagnosis. We took a step forward and included 
studies describing low BMI, vitamin deficiencies, 
pancreatic insufficiency, and keeping pulmonary 
exacerbation as the main emphasis. 
The current review had certain limitations as it could not 
find any study from South Asia representing the risk 
factors prevalent in this region. Non-indexed journals and 
grey literature were not reviewed. Despite the limitations, 
however, the review calculated risk of bias for studies 
using standardized tools, such as NOS and the Cochrane 
risk of bias tools.5,6 Also, to our knowledge, the current 
review is the first to highlight major risk factors associated 
with pulmonary exacerbation that can be used as a guide 
for future research. On the basis of findings, we strongly 
stress the need for research in the domains of causes, 
identification of risk factors, and their roles in overall 
management of pulmonary exacerbations in CF cases. 
Conclusion 
Early detection of risk factors can result in prompt 
diagnosis and abate  grave outcomes, reducing overall 
disease burden and mortality related to pulmonary 
exacerbations. This can lead to an overall reduced strain 
on healthcare, ensuring collective cost-effective and 
efficient management of CF. 
Disclaimer: None. 
Conflict of Interest: None. 
Source of Funding: None. 
References 
 
1. Tangpricha V, Smith EM, Binongo J, Judd SE, Ziegler TR, Walker S, 
et al. The Vitamin D for Enhancing the Immune System in Cystic 
Fibrosis (DISC) trial: Rationale and design of a multi-center, 
double-blind, placebo-controlled trial of high dose bolus 
administration of vitamin D3 during acute pulmonary 
exacerbation of cystic fibrosis. Contemp Clin Trials Commun. 
2017; 6:39-45. 
2. Ong T, Schechter M, Yang J, Peng L, Emerson J, Gibson RL, et al. 
EPIC Study Group. Socioeconomic Status, Smoke Exposure, and 
Health Outcomes in Young Children With Cystic Fibrosis. 
Pediatrics. 2017; 139:e20162730.  
3. Goss CH. Acute Pulmonary Exacerbations in Cystic Fibrosis. Semin 
Respir Crit Care Med. 2019; 40:792-803. 
4.  Liberati A, Altman D, Tetzlaff J, Mulrow C, Gotzsche P, Ioannidis J, 
et al. The PRISMA statement for reporting systematic reviews and 
meta-analyses of studies that evaluate healthcare interventions: 
explanation and elaboration. BMJ. 2009; 339:b2700. 
5.    Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. 
The Newcastle-Ottawa Scale (NOS) for assessing the quality of 
nonrandomised studies in meta-analyse 2008.[Online] [Cited 
2020 May 12]. Available from: URL:  
http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp 
6. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, 
et al. Cochrane Bias Methods Group; Cochrane Statistical Methods 
Group. The Cochrane Collaboration's tool for assessing risk of bias 
in randomised trials. BMJ. 2011; 10:343:d5928. 
7.      Geborek A, Hjelte L. Association between genotype and 
pulmonary phenotype in cystic fibrosis patients with severe 
mutations. J Cyst Fibros. 2011; 10:187-92. 
8. Loubières Y, Grenet D, Simon-Bouy B, Medioni J, Landais P, Férec 
C, et al. Association between genetically determined pancreatic 
status and lung disease in adult cystic fibrosis patients. Chest. 
2002; 121:73-80. 
9. Cogen J, Emerson J, Sanders DB, Ren C, Schechter MS, Gibson RL, 
et al. Risk factors for lung function decline in a large cohort of 
young cystic fibrosis patients: Lung Function Decline Risk Factors 
in Pediatric CF. Pediatr Pulmonol. 2015; 50:763-70. 
10. Corey M, Edwards L, Levison H, Knowles M. Longitudinal analysis 
of pulmonary function decline in patients with cystic fibrosis. J 
Pediatr. 1997; 131:809-14. 
11. Aaron SD, Ramotar K, Ferris W, Vandemheen K, Saginur R, Tullis E, 
et al. Adult cystic fibrosis exacerbations and new strains of 
Pseudomonas aeruginosa. Am J Respir Crit Care Med. 2004; 
169:811-5. 
12. Mayer-Hamblett N, Rosenfeld M, Gibson RL, Ramsey BW, 
Kulasekara HD, Retsch-Bogart GZ, et al. Pseudomonas aeruginosa 
in vitro phenotypes distinguish cystic fibrosis infection stages and 
outcomes. Am J Respir Crit Care Med. 2014; 190:289-97.  
13. Horsley A, Jones AM. Antibiotic treatment for Burkholderia 
cepacia complex in people with cystic fibrosis experiencing a 
Vol. 71, No. 9, September 2021
Risk factors leading to pulmonary exacerbation in patients with cystic fibrosis: A systematic review2222
pulmonary exacerbation. Cochrane Database Syst Rev. 2012; 
10:CD009529. 
14. Waters V, Yau Y, Prasad S, Lu A, Atenafu E, Crandall I, et al. 
Stenotrophomonas maltophilia in cystic fibrosis: serologic 
response and effect on lung disease: Serologic response and 
effect on lung disease. Am J Respir Crit Care Med. 2011; 183:635-
40. 
15. Flight WG, Bright-Thomas RJ, Tilston P, Mutton KJ, Guiver M, 
Morris J, et al. Incidence and clinical impact of respiratory viruses 
in adults with cystic fibrosis. Thorax. 2014; 69:247-53. 
16. Quon BS, Dai DLY, Hollander Z, Ng RT, Tebbutt SJ, Man SFP, et al. 
Discovery of novel plasma protein biomarkers to predict 
imminent cystic fibrosis pulmonary exacerbations using multiple 
reaction monitoring mass spectrometry. Thorax. 2016; 71:216-22.  
17. Reid DW, Misso N, Aggarwal S, Thompson PJ, Walters EH. 
Oxidative stress and lipid-derived inflammatory mediators during 
acute exacerbations of cystic fibrosis. Respirology. 2007; 12:63-9.  
18. Wojewodka G, De Sanctis JB, Bernier J, Bérubé J, Ahlgren HG, 
Gruber J, et al. Candidate markers associated with the probability 
of future pulmonary exacerbations in cystic fibrosis patients. PLoS 
One. 2014; 9:e88567.  
19. Taylor CJ, McGaw J, Rigby AS, Threlfall D, Karmel J. Pilot safety 
study of liposomal prostaglandin (PGE1) in respiratory 
exacerbations in cystic fibrosis. J Cyst Fibros. 2002; 1:90-3. 
20. McGrath LT, Mallon P, Dowey L, Silke B, McClean E, McDonnell M, 
et al. Oxidative stress during acute respiratory exacerbations in 
cystic fibrosis. Thorax. 1999; 54:518-23. 
21. Laguna TA, Wagner BD, Luckey HK, Mann SA, Sagel SD, 
Regelmann W, et al. Sputum desmosine during hospital 
admission for pulmonary exacerbation in cystic fibrosis. Chest. 
2009; 136:1561-8.  
22. Louw JJ, Toelen J, Proesmans M, Vermeulen F, Billen J, de Boeck K. 
Serum procalcitonin is not an early marker of pulmonary 
exacerbation in children with cystic fibrosis. Eur J Pediatr. 2012; 
171:139-42.  
23. Quon BS, Ngan DA, Wilcox PG, Man SFP, Sin DD. Plasma sCD14 as 
a biomarker to predict pulmonary exacerbations in cystic fibrosis. 
PLoS One. 2014; 9:e89341. 
24. Gray RD, Imrie M, Boyd AC, Porteous D, Innes JA, Greening AP. 
Sputum and serum calprotectin are useful biomarkers during CF 
exacerbation. J Cyst Fibros. 2010; 9:193-8. 
25. McColley SA, Stellmach V, Boas SR, Jain M, Crawford SE. Serum 
vascular endothelial growth factor is elevated in cystic fibrosis 
and decreases with treatment of acute pulmonary exacerbation. 
Am J Respir Crit Care Med. 2000; 161:1877-80. 
26. Kerem E, Viviani L, Zolin A, MacNeill S, Hatziagorou E, Ellemunter 
H, et al. Factors associated with FEV1 decline in cystic fibrosis: 
analysis of the ECFS patient registry. Eur Respir J. 2014; 43:125-33.  
27. McPhail GL, Acton JD, Fenchel MC, Amin RS, Seid M. 
Improvements in lung function outcomes in children with cystic 
fibrosis are associated with better nutrition, fewer chronic 
pseudomonas aeruginosa infections, and dornase alfa use. J 
Pediatr. 2008; 153:752-7.  
28. Yen EH, Quinton H, Borowitz D. Better nutritional status in early 
childhood is associated with improved clinical outcomes and 
survival in patients with cystic fibrosis. J Pediatr. 2013; 162:530-5. 
29. Grossmann RE, Zughaier SM, Liu S, Lyles RH, Tangpricha V. Impact 
of vitamin D supplementation on markers of inflammation in 
adults with cystic fibrosis hospitalized for a pulmonary 
exacerbation. Eur J Clin Nutr. 2012; 66:1072-4. 
30. McCauley LA, Thomas W, Laguna TA, Regelmann WE, Moran A, 
Polgreen LE. Vitamin D deficiency is associated with pulmonary 
exacerbations in children with cystic fibrosis. Ann Am Thorac Soc. 
2014; 11:198-204. 
31. Chalmers JD, McHugh BJ, Docherty C, Govan JRW, Hill AT. Vitamin-
D deficiency is associated with chronic bacterial colonisation and 
disease severity in bronchiectasis. Thorax. 2013; 68:39-47. 
32. Blatter J, Brehm JM, Sordillo J, Forno E, Boutaoui N, Acosta-Pérez 
E, et al. Folate deficiency, atopy, and severe asthma exacerbations 
in Puerto rican children. Ann Am Thorac Soc. 2016; 13:223-30. 
33. Duggan C, Colin AA, Agil A, Higgins L, Rifai N. Vitamin A status in 
acute exacerbations of cystic fibrosis. Am J Clin Nutr. 1996; 64:635-
9. 
34. Lagrange-Puget M, Durieu I, Ecochard R, Abbas-Chorfa F, Drai J, 
Steghens J-P, et al. Longitudinal study of oxidative status in 312 
cystic fibrosis patients in stable state and during bronchial 
exacerbation. Pediatr Pulmonol. 2004; 38:43-9. 
35. Kopp BT, Nicholson L, Paul G, Tobias J, Ramanathan C, Hayes D Jr. 
The geographic impact on hospitalization in patients with cystic 
fibrosis. J Pediatr. 2016; 170:246-52. 
36. Schechter MS, McColley SA, Regelmann W, Millar SJ, Pasta DJ, 
Wagener JS, et al. Socioeconomic status and the likelihood of 
antibiotic treatment for signs and symptoms of pulmonary 
exacerbation in children with cystic fibrosis. J Pediatr. 2011; 
159:819-24. 
37. Harun SN, Wainwright C, Klein K, Hennig S. A systematic review of 
studies examining the rate of lung function decline in patients 
with cystic fibrosis. Paediatr Respir Rev. 2016; 20:55-66.
J Pak Med Assoc
D. A. Aziz, S. K. Fatima, H. N. Tahir 2223
